company background image
NECLIFE logo

Nectar Lifesciences NSEI:NECLIFE Rapporto sulle azioni

Ultimo prezzo

₹39.69

Cap. di mercato

₹8.9b

7D

19.3%

1Y

64.3%

Aggiornato

04 Nov, 2024

Dati

Dati finanziari dell'azienda

Nectar Lifesciences Limited

NSEI:NECLIFE Rapporto sulle azioni

Cap. di mercato: ₹8.9b

NECLIFE Panoramica delle azioni

Nectar Lifesciences Limited produce e vende prodotti farmaceutici in India e a livello internazionale.

Informazioni sull'azienda

NECLIFE analisi fondamentale
Punteggio fiocco di neve
Valutazione2/6
Crescita futura0/6
Prestazioni passate2/6
Salute finanziaria4/6
Dividendi0/6

Premi

Trading at 78.6% below our estimate of its fair value
Became profitable this year

Analisi del rischio

Interest payments are not well covered by earnings
Earnings have declined by 20.7% per year over past 5 years
Highly volatile share price over the past 3 months compared to the Indian market

Nectar Lifesciences Limited Concorrenti

Wanbury

BSE:524212

₹7.6b

Albert David

BSE:524075

₹8.0b

Ind-Swift Laboratories

NSEI:INDSWFTLAB

₹6.9b

NGL Fine-Chem

BSE:524774

₹12.4b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Nectar Lifesciences
Prezzi storici delle azioni
Prezzo attuale dell'azione₹39.69
Massimo di 52 settimane₹56.50
Minimo di 52 settimane₹23.25
Beta1.01
1Variazione di 1 mese-5.36%
Variazione a 3 mesi33.55%
Variazione di 1 anno64.35%
3Variazione a 3 anni48.10%
Variazione a 5 anni171.85%
Variazione dall'IPO52.60%

Notizie e aggiornamenti recenti

Revenues Working Against Nectar Lifesciences Limited's (NSE:NECLIFE) Share Price Following 26% Dive

Oct 11
Revenues Working Against Nectar Lifesciences Limited's (NSE:NECLIFE) Share Price Following 26% Dive

Recent updates

Revenues Working Against Nectar Lifesciences Limited's (NSE:NECLIFE) Share Price Following 26% Dive

Oct 11
Revenues Working Against Nectar Lifesciences Limited's (NSE:NECLIFE) Share Price Following 26% Dive

Nectar Lifesciences Limited (NSE:NECLIFE) Shares Fly 31% But Investors Aren't Buying For Growth

Aug 22
Nectar Lifesciences Limited (NSE:NECLIFE) Shares Fly 31% But Investors Aren't Buying For Growth

Here's Why Nectar Lifesciences (NSE:NECLIFE) Has A Meaningful Debt Burden

Jul 27
Here's Why Nectar Lifesciences (NSE:NECLIFE) Has A Meaningful Debt Burden

Nectar Lifesciences Limited (NSE:NECLIFE) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Feb 19
Nectar Lifesciences Limited (NSE:NECLIFE) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Does Nectar Lifesciences (NSE:NECLIFE) Have A Healthy Balance Sheet?

Dec 22
Does Nectar Lifesciences (NSE:NECLIFE) Have A Healthy Balance Sheet?

Nectar Lifesciences (NSE:NECLIFE) Has Debt But No Earnings; Should You Worry?

Jun 16
Nectar Lifesciences (NSE:NECLIFE) Has Debt But No Earnings; Should You Worry?

Nectar Lifesciences (NSE:NECLIFE) Takes On Some Risk With Its Use Of Debt

Jun 21
Nectar Lifesciences (NSE:NECLIFE) Takes On Some Risk With Its Use Of Debt

Nectar Lifesciences (NSE:NECLIFE) Takes On Some Risk With Its Use Of Debt

Jul 29
Nectar Lifesciences (NSE:NECLIFE) Takes On Some Risk With Its Use Of Debt

Is Nectar Lifesciences Limited (NSE:NECLIFE) A Risky Dividend Stock?

Feb 25
Is Nectar Lifesciences Limited (NSE:NECLIFE) A Risky Dividend Stock?

Nectar Lifesciences (NSE:NECLIFE) Has A Somewhat Strained Balance Sheet

Jan 21
Nectar Lifesciences (NSE:NECLIFE) Has A Somewhat Strained Balance Sheet

Zooming in on NSE:NECLIFE's 0.3% Dividend Yield

Nov 02
Zooming in on NSE:NECLIFE's 0.3% Dividend Yield

Does Nectar Lifesciences (NSE:NECLIFE) Have A Healthy Balance Sheet?

Sep 07
Does Nectar Lifesciences (NSE:NECLIFE) Have A Healthy Balance Sheet?

If You Had Bought Nectar Lifesciences (NSE:NECLIFE) Stock A Year Ago, You Could Pocket A 47% Gain Today

Aug 09
If You Had Bought Nectar Lifesciences (NSE:NECLIFE) Stock A Year Ago, You Could Pocket A 47% Gain Today

The Nectar Lifesciences (NSE:NECLIFE) Share Price Has Gained 47% And Shareholders Are Hoping For More

Aug 09
The Nectar Lifesciences (NSE:NECLIFE) Share Price Has Gained 47% And Shareholders Are Hoping For More

What You Can Learn From Nectar Lifesciences Limited's (NSE:NECLIFE) P/E

Jul 13
What You Can Learn From Nectar Lifesciences Limited's (NSE:NECLIFE) P/E

Rendimenti per gli azionisti

NECLIFEIN PharmaceuticalsIN Mercato
7D19.3%2.0%1.8%
1Y64.3%58.6%36.8%

Ritorno vs Industria: NECLIFE exceeded the Indian Pharmaceuticals industry which returned 58.6% over the past year.

Rendimento vs Mercato: NECLIFE exceeded the Indian Market which returned 36.8% over the past year.

Volatilità dei prezzi

Is NECLIFE's price volatile compared to industry and market?
NECLIFE volatility
NECLIFE Average Weekly Movement9.7%
Pharmaceuticals Industry Average Movement6.3%
Market Average Movement6.3%
10% most volatile stocks in IN Market9.4%
10% least volatile stocks in IN Market4.0%

Prezzo delle azioni stabile: NECLIFE's share price has been volatile over the past 3 months compared to the Indian market.

Volatilità nel tempo: NECLIFE's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Indian stocks.

Informazioni sull'azienda

FondatoI dipendentiAMMINISTRATORE DELEGATOSito web
19951,686Amit Chadahwww.neclife.com

Nectar Lifesciences Limited produce e vende prodotti farmaceutici in India e a livello internazionale. Gli ingredienti farmaceutici attivi e intermedi dell'azienda comprendono cefixime, cefuroxime axetil amorfo, cefuroxime axetil cristallino, cefotaxime sodico, ceftriaxone sodico, cefixime triidrato, cefuroxime axetil, cefpodoxime proxetil e sterile, cefprozil, cefdinir, cefuroxime sodico, cefazolina sodica, ceftazidime pentaidrato e cefepime +Arginina. L'azienda offre anche la produzione a contratto di forme di dosaggio finite, come compresse, capsule, sospensioni orali in polvere secca, granuli e iniettabili per le cefalosporine.

Nectar Lifesciences Limited Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Nectar Lifesciences con la sua capitalizzazione di mercato?
NECLIFE statistiche fondamentali
Capitalizzazione di mercato₹8.90b
Guadagni(TTM)₹61.44m
Ricavi(TTM)₹16.49b

144.9x

Rapporto P/E

0.5x

Rapporto P/S

NECLIFE è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
NECLIFE Conto economico (TTM)
Ricavi₹16.49b
Costo del fatturato₹11.60b
Profitto lordo₹4.89b
Altre spese₹4.83b
Guadagni₹61.44m

Ultimi guadagni dichiarati

Jun 30, 2024

Prossima data di guadagno

Nov 14, 2024

Utile per azione (EPS)0.27
Margine lordo29.64%
Margine di profitto netto0.37%
Rapporto debito/patrimonio netto59.4%

Come si è comportato NECLIFE nel lungo periodo?

Vedi performance storica e confronto